Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IART 
Integra LifeSciences Holdings (IART)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: IART (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.88
1 Year Target Price $15.88
| 2 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 2 | Sell |
| 2 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.6% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.16B USD | Price to earnings Ratio - | 1Y Target Price 15.88 |
Price to earnings Ratio - | 1Y Target Price 15.88 | ||
Volume (30-day avg) 12 | Beta 1.17 | 52 Weeks Range 11.06 - 27.13 | Updated Date 08/29/2025 |
52 Weeks Range 11.06 - 27.13 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-31 | When - | Estimate 0.44 | Actual 0.45 |
Profitability
Profit Margin -30.87% | Operating Margin (TTM) 7.86% |
Management Effectiveness
Return on Assets (TTM) 2.42% | Return on Equity (TTM) -38.92% |
Valuation
Trailing PE - | Forward PE 6.68 | Enterprise Value 2916357123 | Price to Sales(TTM) 0.71 |
Enterprise Value 2916357123 | Price to Sales(TTM) 0.71 | ||
Enterprise Value to Revenue 1.8 | Enterprise Value to EBITDA 14.27 | Shares Outstanding 77910800 | Shares Floating 59268296 |
Shares Outstanding 77910800 | Shares Floating 59268296 | ||
Percent Insiders 13.96 | Percent Institutions 95.24 |
Upturn AI SWOT
Integra LifeSciences Holdings
Company Overview
History and Background
Integra LifeSciences Holdings Corporation was founded in 1989. It has grown through organic growth and acquisitions, focusing on regenerative medicine and neurosurgery.
Core Business Areas
- Codman Specialty Surgical (CSS): Focuses on neurosurgery products, including implants, instruments, and devices for cranial stabilization, neuromonitoring, and CSF management.
- Tissue Technologies: Specializes in advanced wound care and reconstructive surgery products, utilizing collagen-based technology.
Leadership and Structure
Jan De Witte serves as the CEO. The company is structured with executive leadership overseeing the two main business segments and supporting corporate functions.
Top Products and Market Share
Key Offerings
- DuraGen: A dural regeneration matrix used in neurosurgery to repair dura mater. Competitors: Baxter International, Medtronic. Market share is estimated around 30% within the dural repair market.
- CerebroFlo: An external CSF drainage system. Competitors include Medtronic and Johnson & Johnson. Market share is estimated around 20% in the external drainage market.
- Integra Skin: A regenerative skin product for wound care and burn treatment. Competitors: Smith & Nephew, Organogenesis. Market share is estimated around 10% in the advanced wound care market.
Market Dynamics
Industry Overview
The medical device industry is experiencing growth due to an aging population, technological advancements, and increased demand for minimally invasive procedures.
Positioning
Integra LifeSciences holds a strong position in the neurosurgery and advanced wound care markets, with a competitive advantage stemming from its collagen-based technology and established relationships with surgeons.
Total Addressable Market (TAM)
The estimated TAM for Integra's key markets is $8 billion. Integra's position allows it to address a significant portion of the TAM, focusing on high-growth areas.
Upturn SWOT Analysis
Strengths
- Strong brand reputation in neurosurgery
- Proprietary collagen technology platform
- Established relationships with surgeons
- Diversified product portfolio
Weaknesses
- High reliance on key products
- Exposure to pricing pressures
- Dependence on acquisitions for growth
- Integration challenges with acquired businesses
Opportunities
- Expanding into emerging markets
- Developing new products through R&D
- Acquiring complementary businesses
- Leveraging digital technologies
Threats
- Increased competition from larger players
- Regulatory changes
- Economic downturns
- Product liability lawsuits
Competitors and Market Share
Key Competitors
- MDT
- BSX
- JNJ
Competitive Landscape
Integra faces competition from larger medical device companies. Integra's focus on neurosurgery and wound care provides a niche, but it must continue to innovate and expand its product offerings to maintain its competitive position.
Major Acquisitions
Acquired Company Name
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Explain the strategic reasons behind the acquisition.
Growth Trajectory and Initiatives
Historical Growth: Integra has experienced moderate revenue growth through a combination of organic initiatives and strategic acquisitions.
Future Projections: Analyst estimates project moderate revenue growth in the coming years, driven by new product launches and market expansion.
Recent Initiatives: Recent initiatives include the launch of new neurosurgery products and investments in R&D to develop innovative technologies.
Summary
Integra LifeSciences is a mid-sized player in a competitive market with good positions in neurosurgery and wound care. Its collagen technology provides a strong base for growth. However, Integra faces threats from larger competitors and integration challenges from its acquisitive strategy.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Integra LifeSciences Holdings
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 1995-08-16 | President, CEO & Director Ms. Mojdeh Poul | ||
Sector Healthcare | Industry Medical Devices | Full time employees 4396 | Website https://www.integralife.com |
Full time employees 4396 | Website https://www.integralife.com | ||
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.